Anita Afzali

Anita Afzali is a physician-scientist specializing in Inflammatory Bowel Disease (IBD), with a focus on real-world clinical outcomes, biologics, and transition of care. She holds a Bachelor's in Genetics and Cell Biology from Washington State University (2001) and an MD from the University of Washington (2006). Certified in Gastroenterology by the American Board of Internal Medicine (2013, recertified 2019), she has led industry-funded grants assessing Vedolizumab, Ustekinumab, and Etrasimod for IBD therapies.

• Education: BS in Genetics and Cell Biology (Washington State University, 2001); MD (University of Washington, 2006)
• Certifications: Board certified in Gastroenterology (American Board of Internal Medicine, 2013, recertified 2019)

Her research spans biologics in IBD, pregnancy outcomes with immune-mediated diseases, transitions from pediatric to adult IBD care, and cannabis's impact on IBD. She has collaborated on multi-center trials and published extensively in Clinical and Translational Gastroenterology, The Lancet, and Inflammatory Bowel Diseases. Her publications emphasize real-world data, treatment adherence, and disparities in patient care.

Recent grants include industry-funded studies on Vedolizumab and Ustekinumab for Crohn's disease (2025-2028) and Etrasimod for ulcerative colitis (2025-2028). She has not been explicitly affiliated with a university, school, or department in the provided text.